A Systematic Review on the Role of Βeta-Blockers in Reducing Cardiac Arrhythmias in Long QT Syndrome Subtypes 1-3
Authors:
- Terry R. WentTWTerry R. Went
- Waleed SultanWSWaleed Sultan
- Alisha SapkotaASAlisha Sapkota
- Hajra KhurshidHKHajra Khurshid
- Israa A QureshiIQIsraa A Qureshi
- Anjli TaraATAnjli Tara
- Myat WinMWMyat Win
- Dwayne A WiltshireDWDwayne A Wiltshire
- Amudhan KannanAKAmudhan Kannan
- Sheila W. RuoSRSheila W. Ruo
- Michael AlfonsoMAMichael Alfonso
Open Access
- 1 September 2021
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 13 (9)
Abstract
Long QT syndrome (LQTS) is one of the most common inherited cardiac channelopathies with a prevalence of 1:2000. The condition can be congenital or acquired with 15 recognized genotypes; the most common subtypes are LQTS 1, 2, and 3 making up to 85%-90% of the cases. LQTS is characterized by delayed ventricular cardiomyocyte repolarization manifesting on the surface electrocardiogram (EKG) by a prolonged corrected QT (QTc) interval. The mainstay of treatment for this condition involves in part or combination medical therapy via β-blockers as first-line (or other anti-arrhythmic), left cardiac sympathectomy, or implantable cardiac defibrillator placement. Given the high rate of adverse cardiac events (ACE) or sudden cardiac death (SCD) in this population of patients with this disease, this review seeks to highlight the genotype-specific treatment consensus in β-blocker therapy of the most common subtypes. A database search of PubMed, PMC, and Medline was conducted to ascertain the most recent data in the last five years on the management of LQTS types 1-3 and the role of β-blockers in reducing ACE in these types. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were adhered to in the study selection, and selected studies focused on humans, written in the English Language, and within the last five years of LQTS subtypes 1, 2, and 3. Eleven relevant studies were selected after considering inclusion criteria, exclusion criteria, and quality appraisal within the last five years, focusing on β-blocker selection directed based on the subtypes of LQTS. Two meta-analyses, one cohort study, and eight reviews provided significant data that non-selective β-blockers unequivocally are of benefit in these LQTS types. Summary of findings suggested nadolol followed by propranolol yields the best results in LQTS 1, while nadolol would yield the best effect in LQTS 2 and 3.Keywords
This publication has 28 references indexed in Scilit:
- Update on the Diagnosis and Management of Familial Long QT SyndromeHeart, Lung and Circulation, 2016
- MY APPROACH to treatment of the congenital long QT syndromesTrends in Cardiovascular Medicine, 2015
- Congenital Long QT Syndromes: Prevalence, Pathophysiology and ManagementPediatric Drugs, 2014
- Must every child with long QT syndrome take a beta blocker?Archives of Disease in Childhood, 2014
- Implantable Defibrillators in Long QT Syndrome, Brugada Syndrome, Hypertrophic Cardiomyopathy, and Arrhythmogenic Right Ventricular CardiomyopathyCardiology Clinics, 2014
- A Clinical Approach to Inherited ArrhythmiasCirculation: Cardiovascular Genetics, 2012
- Congenital Long and Short QT SyndromesCardiology, 2012
- Long-QT SyndromeCirculation: Arrhythmia and Electrophysiology, 2012
- β-Blockers Protect Against Dispersion of Repolarization During Exercise in Congenital Long-QT Syndrome Type 1Journal of Cardiovascular Electrophysiology, 2011
- Influence of the Genotype on the Clinical Course of the Long-QT SyndromeNew England Journal of Medicine, 1998